Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

368 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo.
Meuleman P, Catanese MT, Verhoye L, Desombere I, Farhoudi A, Jones CT, Sheahan T, Grzyb K, Cortese R, Rice CM, Leroux-Roels G, Nicosia A. Meuleman P, et al. Among authors: nicosia a. Hepatology. 2012 Feb;55(2):364-72. doi: 10.1002/hep.24692. Epub 2011 Dec 16. Hepatology. 2012. PMID: 21953761 Free PMC article.
Successful anti-scavenger receptor class B type I (SR-BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants with in vitro resistance to SR-BI-targeting agents.
Vercauteren K, Van Den Eede N, Mesalam AA, Belouzard S, Catanese MT, Bankwitz D, Wong-Staal F, Cortese R, Dubuisson J, Rice CM, Pietschmann T, Leroux-Roels G, Nicosia A, Meuleman P. Vercauteren K, et al. Among authors: nicosia a. Hepatology. 2014 Nov;60(5):1508-18. doi: 10.1002/hep.27196. Epub 2014 Jul 30. Hepatology. 2014. PMID: 24797654 Free PMC article.
High-avidity monoclonal antibodies against the human scavenger class B type I receptor efficiently block hepatitis C virus infection in the presence of high-density lipoprotein.
Catanese MT, Graziani R, von Hahn T, Moreau M, Huby T, Paonessa G, Santini C, Luzzago A, Rice CM, Cortese R, Vitelli A, Nicosia A. Catanese MT, et al. Among authors: nicosia a. J Virol. 2007 Aug;81(15):8063-71. doi: 10.1128/JVI.00193-07. Epub 2007 May 16. J Virol. 2007. PMID: 17507483 Free PMC article.
Targeting a host-cell entry factor barricades antiviral-resistant HCV variants from on-therapy breakthrough in human-liver mice.
Vercauteren K, Brown RJ, Mesalam AA, Doerrbecker J, Bhuju S, Geffers R, Van Den Eede N, McClure CP, Troise F, Verhoye L, Baumert T, Farhoudi A, Cortese R, Ball JK, Leroux-Roels G, Pietschmann T, Nicosia A, Meuleman P. Vercauteren K, et al. Among authors: nicosia a. Gut. 2016 Dec;65(12):2029-2034. doi: 10.1136/gutjnl-2014-309045. Epub 2015 Aug 25. Gut. 2016. PMID: 26306759
Combined adenovirus vector and hepatitis C virus envelope protein prime-boost regimen elicits T cell and neutralizing antibody immune responses.
Chmielewska AM, Naddeo M, Capone S, Ammendola V, Hu K, Meredith L, Verhoye L, Rychlowska M, Rappuoli R, Ulmer JB, Colloca S, Nicosia A, Cortese R, Leroux-Roels G, Balfe P, Bienkowska-Szewczyk K, Meuleman P, McKeating JA, Folgori A. Chmielewska AM, et al. Among authors: nicosia a. J Virol. 2014 May;88(10):5502-10. doi: 10.1128/JVI.03574-13. Epub 2014 Mar 5. J Virol. 2014. PMID: 24599994 Free PMC article.
368 results